198
Participants
Start Date
January 22, 2024
Primary Completion Date
August 31, 2027
Study Completion Date
December 31, 2029
Dostarlimab
Intravenous (IV) infusion
Bevacizumab
Intravenous (IV) infusion
Doxorubicin
Intravenous (IV) infusion
Gemcitabine
Intravenous (IV) infusion
Paclitaxel
Intravenous (IV) infusion
Pegylated liposomal doxorubicin
Intravenous (IV) infusion
RECRUITING
Kurume University Hospital, Kurume
RECRUITING
Fukushima Medical University Hospital, Fukushima
RECRUITING
Mie University Hospital, Tsu
RECRUITING
Tohoku University Hospital, Sendai
RECRUITING
Niigata Cancer Center Hospital, Niigata
RECRUITING
Saitama Medical University International Medical Center, Hidaka
RECRUITING
Tokushima University Hospital, Tokushima
RECRUITING
The Jikei University Hospital, Tokyo
RECRUITING
The Cancer Institute Hospital Of JFCR, Tokyo
RECRUITING
University of Tsukuba Hospital, Tsukuba
NOT_YET_RECRUITING
National University Hospital, Singapore
RECRUITING
National Cancer Center, Goyang-si
RECRUITING
Bundang Seoul National University Hospital, Seongnam-si
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Korea University Guro Hospital, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University, Seoul
RECRUITING
Severance Hospital, Yonsei Health System, Seoul
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Yonsei University
OTHER